AR100289A1 - Formas de un inhibidor de pi3k - Google Patents

Formas de un inhibidor de pi3k

Info

Publication number
AR100289A1
AR100289A1 ARP150101368A ARP150101368A AR100289A1 AR 100289 A1 AR100289 A1 AR 100289A1 AR P150101368 A ARP150101368 A AR P150101368A AR P150101368 A ARP150101368 A AR P150101368A AR 100289 A1 AR100289 A1 AR 100289A1
Authority
AR
Argentina
Prior art keywords
forms
pi3k inhibitor
purin
quinolinyl
pyridinyl
Prior art date
Application number
ARP150101368A
Other languages
English (en)
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR100289A1 publication Critical patent/AR100289A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan formas de hidrato y anhidrato de N-((1S)-1-(7-flúor-2-(2-piridinil)-3-quinolinil)etil)-9H-purin-6-amina. Se proporcionan además composiciones farmacéuticas que contienen las formas, y métodos para el uso de dichas composiciones para el tratamiento del cáncer.
ARP150101368A 2014-05-06 2015-05-06 Formas de un inhibidor de pi3k AR100289A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461989383P 2014-05-06 2014-05-06

Publications (1)

Publication Number Publication Date
AR100289A1 true AR100289A1 (es) 2016-09-21

Family

ID=53190052

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101368A AR100289A1 (es) 2014-05-06 2015-05-06 Formas de un inhibidor de pi3k

Country Status (3)

Country Link
AR (1) AR100289A1 (es)
TW (1) TW201625621A (es)
WO (1) WO2015171725A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2023016477A1 (en) * 2021-08-11 2023-02-16 Taizhou Eoc Pharma Co., Ltd. A cyclin-dependent kinase inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ579834A (en) 2007-03-23 2012-03-30 Amgen Inc Heterocyclic compounds as selective inhibitors of PI3K activity
ME02473B (me) 2012-04-04 2017-02-20 Amgen Inc Heterociklična jedinjenja i njihova primjena

Also Published As

Publication number Publication date
TW201625621A (zh) 2016-07-16
WO2015171725A1 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2018001230A1 (es) Tratamiento de osteoartritis
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2015002932A1 (es) Inhibidores de proteína quinasa
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2016002495A1 (es) Derivados de piridina macrocíclicos .
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
DK3119762T3 (da) Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft
CL2015002151A1 (es) Biaril amide compuestos como inhibidores de quinasa
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
CL2015002628A1 (es) Compuestos de heteroarilo y sus usos.
UY36175A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2016003214A1 (es) Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
BR112017000730B8 (pt) Derivados de pirrolidinona como inibidores de metap-2, e medicamentos
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы

Legal Events

Date Code Title Description
FB Suspension of granting procedure